[1]长短效重组人粒细胞刺激因子治疗Ⅳ度骨髓抑制的疗效评价和成本效果分析 [2]长短效重组人粒细胞刺激因子治疗Ⅳ度骨髓抑制的疗效评价和成本效果分析 [3]两种呕吐治疗方案的成本－效果分析 [4]基于成本-效果分析的新辅助化疗联合手术与单纯手术治疗晚期食管癌的经济学评价 [5]3种放疗、化疗后粒细胞减少症治疗方案的成本-效果分析 [6]药物经济学的研究现状与展望 [7]Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma [8]Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis [9]Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC [10]Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.